论文部分内容阅读
目的探讨选择性雌激素受体拮抗剂雷洛昔芬对大鼠垂体瘤GH3细胞株的seladin-1基因表达及其对瘤细胞增殖的影响。方法以不同浓度(0.1～1 000 nmol/L)的雷洛昔芬作用于大鼠GH3细胞,培养48 h后检测雷洛昔芬的作用效果;荧光定量RT-PCR和Western blot分别检测seladin-1mRNA和蛋白;Cell Counting Kit-8试剂盒检测不同浓度药物对瘤细胞增殖的影响。结果雷洛昔芬在10～100 nmol/L的浓度范围能有效抑制selandin-1的表达,瘤细胞增殖受抑制(P<0.05)。结论雷洛昔芬能够有效抑制大鼠垂体瘤GH3细胞株selandin-1表达及瘤细胞生长,可作为垂体瘤的药物和基因治疗的新靶点。
Objective To investigate the effect of raloxifene, a selective estrogen receptor antagonist, on the expression of seladin-1 in rat pituitary adenoma GH3 cell line and its effect on tumor cell proliferation. Methods Raloxifene in different concentrations (0.1 ~ 1 000 nmol / L) was used to treat rat GH3 cells and the effect of raloxifene was detected after 48 h of culture. The expression of seladin- 1 mRNA and protein; Cell Counting Kit-8 kit to detect different concentrations of drugs on tumor cell proliferation. Results Raloxifene could effectively inhibit the expression of selandin-1 in the concentration range of 10 ~ 100 nmol / L, and the proliferation of tumor cells was inhibited (P <0.05). Conclusion raloxifene can effectively inhibit the expression of selandin-1 and the growth of tumor cells in the rat pituitary adenoma GH3 cell line, which can be used as a new target of drug and gene therapy for pituitary adenoma.